Equfina 50 mg
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Parkinson Disease
Conditions
Parkinson Disease
Trial Timeline
Jun 3, 2021 → Mar 20, 2025
NCT ID
NCT05225324About Equfina 50 mg
Equfina 50 mg is a pre-clinical stage product being developed by Eisai for Parkinson Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05225324. Target conditions include Parkinson Disease.
What happened to similar drugs?
20 of 20 similar drugs in Parkinson Disease were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05225324 | Pre-clinical | Completed |
Competing Products
20 competing products in Parkinson Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| exidavnemab + Placebo Comparator | BioArctic AB | Phase 2 | 36 |
| UB-312 + Placebo | Vaxxinity | Phase 1 | 19 |
| NAV5001 + DaTscan | Navidea Biopharmaceuticals | Phase 3 | 22 |
| LY4006896 + Placebo | Eli Lilly | Phase 1 | 36 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 17 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | 35 |
| Mirabegron + Placebo | Astellas Pharma | Approved | 43 |
| E2007 | Eisai | Phase 3 | 32 |
| ARICEPT | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Phase 3 | 32 |
| GPI 1485 | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 3 | 40 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | 40 |
| Equfina | Eisai | Pre-clinical | 26 |
| perampanel + placebo | Eisai | Phase 2 | 27 |
| Lemborexant + placebo | Eisai | Approved | 50 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | 32 |
| Safinamide Mesilate | Eisai | Approved | 43 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | 35 |
| E2007 | Eisai | Phase 2 | 35 |